UBE2C and cancer: Nevertheless, we further found that high co-expression of UBE2C and cancer stemness markers, including CD44, D166 and EpCAM, have even worse poor prognosis in TSCC patients, which provided potential diagnostic and prognostic markers in oral cancer patients.